Biocracked
Approach 2, lab in action, with palette D, bold color field.

Straight-on, slightly elevated close shot of a gloved hand in a pale nitrile glove holding a glass syringe with a fine needle. The syringe is filled with clear liquid and sits over a row of small glass vials in a matte white rack. The whole scene sits against a saturated tomato-red seamless backdrop. Soft, even studio light gives crisp highlights along the syringe barrel and the vial glass, plus gentle warm-red reflections on the surfaces. A thin electric green (#00e676) cap on one vial is the only small accent. The dosing markings on the syringe are blurred and unreadable. Shallow depth of field blurs the back vials into soft shapes. The mood is precise, clinical and investigational, with high contrast and a measured, careful feel. No text, no labels, no logos.
Research

CBL-514 Dosages - what does science say?

Dr. Synapse · · 5 min read

CBL-514 Dosages - what does science say?

Read this first: CBL-514 is an investigational injectable studied in clinical trials. It is not an oral dose, not a supplement, not an approved product, and nothing here is a recommendation. The "600 mg" figure that circulates online is a per-treatment cap in a supervised trial protocol, tied to a specific injection volume, treatment area and schedule. It is not a serving size. (Note the spelling: CBL-514, not "CL-514".)

CBL-514 comes from Caliway Biopharmaceuticals and is described as a small-molecule injection lipolysis agent. In the papers, it is given as subcutaneous injections into the abdomen by trial investigators. The proposed mechanism, based on nonclinical work cited to unpublished company reports, is targeted fat-cell (adipocyte) apoptosis. It is not a higher metabolic rate, not systemic "fat burning," and not whole-body weight loss. The papers do not disclose the molecule's chemical structure.

Step one: the Phase 2a dose-finding study

The earlier study is Goodman et al., Aesthetic Surgery Journal 2022 (PMC9384315). It was open-label with no placebo, and small: n=43, split 7 / 18 / 18 across three dose levels.

The unit dose was expressed per square centimetre of treated skin, over a 150 cm² area:

Dose level Per-session total (150 cm²)
1.2 mg/cm² 180 mg
1.6 mg/cm² 240 mg
2.0 mg/cm² 300 mg

Sessions used up to 60 injections at 2-week intervals. The mg figure is simply concentration per area multiplied by area. For example, 2.0 mg/cm² × 150 cm² = 300 mg.

The paper reports intention-to-treat (ITT) percent reductions for each dose group, and readers should go to the paper for those figures. The number most often quoted is 24.96%. That is a per-protocol (PP) result, for the 2.0 mg/cm² group, at the first follow-up, corresponding to −119.82 mL of fat volume. A PP number is a favourable subset: it counts only participants who followed the protocol closely. It should not be treated as the headline result for everyone who was enrolled.

Step two: the placebo-controlled Phase 2

The main paper is Gold et al., Aesthetic Surgery Journal 2025;45(6):611-620 (PMC12080885; PubMed; DOI). It was randomized, single-blind (participants only) and placebo-controlled, and ran at five centers in the US and Australia.

The unit dose stayed at 2.0 mg/cm². Almost everything around it changed:

  • Treatment area: 300 cm² for the volume calculation, double the Phase 2a area.
  • Injections: 25 to 50 per treatment, at the investigator's discretion based on how much abdominal fat was present.
  • Each injection: 2.4 mL, spaced 2.45 cm apart.
  • Cap: up to 600 mg per treatment (2.0 mg/cm² × 300 cm²).
  • Schedule: up to 4 treatments at 4-week intervals, with follow-up at 4 and 8 weeks after the last one.
  • Control: normal saline in an equivalent volume.

The comparator was saline placebo, randomized 2:1.

Why mg totals are not interchangeable

The jump from 300 mg to 600 mg does not mean the dose "doubled" in any biological sense. The per-area dose was identical at 2.0 mg/cm². Only the treated territory grew. Across the two trials, the area, the maximum injection count, the interval between sessions and the study design all differ. A total in mg only means something alongside area, volume per injection, spacing, schedule, and who delivered it and how.

That is why a supplement-style reading of "600 mg" is misleading. The number describes a ceiling for a clinician-delivered, area-based injection series. It says nothing about what an individual would absorb or tolerate outside that framework.

No head-to-head comparison of unit doses in Phase 2

The Phase 2 trial did not randomize participants to different unit doses against placebo. 2.0 mg/cm² was locked in based on the earlier work. So the placebo-controlled evidence supports one protocol, not a dose-response curve. The only multi-dose comparison is the small, open-label Phase 2a study, which has no placebo arm.

What the Phase 2 trial found at that protocol

The authors report that the study met its primary and secondary endpoints. In ITT analysis, 63.9% (23/36) of CBL-514 participants lost at least 150 mL of subcutaneous fat volume at the 4-week follow-up, versus 17.4% (4/23) on placebo. At 8 weeks it was 69.6% (16/23) versus 0.0% (0/16). Denominators shrank because follow-up data went missing.

The least-squares mean between-group difference was −206.62 mL at 4 weeks and −216.28 mL at 8 weeks. Fat volume was estimated from ultrasound at four points and a 300 cm² area, not measured directly.

There are important caveats:

  • Of 75 treated participants, 37 did not complete the study (49.3%).
  • The PP population was only 30 people.
  • The sponsor was involved in design, analysis and writing.
  • Investigators were unblinded.
  • The sample size was exploratory.
  • Body weight did not meaningfully change, so this is local fat-volume reduction, not weight loss.

Safety at the trial doses

Safety was tracked through treatment-emergent adverse events, labs, vitals, ECGs, physical exams, and injection-site reactions recorded as distinct events for each treatment. Local reactions at the injection site are the main theme to expect from a protocol with dozens of injections per session. Readers should check the papers for the exact incidence figures, including the rate of severe pain, rather than relying on summaries. Four of the 37 non-completers in Phase 2 left because of adverse events.

In Phase 2a, the study team used measures such as anesthetic, ice and antihistamine. That was study conduct, not advice. It tells you how investigators managed an investigational procedure, not what anyone should do themselves.

The papers also noted lipid signals in a few participants who had high baseline lipids. That is an observation in a small number of people, and it is not a proven metabolic side-effect profile. Nothing in these trials establishes systemic effects of CBL-514 either way.

The takeaway for biohackers

The science on CBL-514 dosing is narrow and specific. A small open-label study compared three per-area doses, and a larger but still modest single-blind trial then used one of them (2.0 mg/cm²) over a larger area with a higher per-session cap. Reading "600 mg" as a label dose misses all of that.

CBL-514 is not approved, not a consumer product, and this article is not medical advice.

More from this CBL-514 series

This article is part of our CBL-514 series. For the full Phase 2 trial overview, start here: CBL-514 Injection Lipolysis: A Phase 2 Map of the Evidence.

Original study

Read the original research on pmc.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach 1, macro science, in palette D, bold color field.

Extreme close-up photograph of a cluster of fat cells (adipocytes) in tissue, shot like a stained microscopy image. Rounded, translucent, pearly-yellow lipid-filled cells press together in a honeycomb. Several in the center look collapsed and shriveled, with ruptured membranes and scattered droplets. A few fine threads of electric green (#00e676) fluorescent stain outline the cell walls. The camera is straight-on at shallow depth of field, with the background cells melting into soft blur. Bright, even transmitted light makes the membranes glow. The backdrop is a saturated magenta-to-tomato-red field that sets off the pale yellow cells. The mood is scrutinizing, skeptical and precise. No text, no labels.
research

CBL-514 fat removal injections: What does the science say?

BY DR. SYNAPSE ·

CBL-514 now has a placebo-controlled Phase 2 randomized trial in Aesthetic Surgery Journal, and the authors report it met its primary and secondary endpoints. But this appraisal shows why the design deserves a hard look: it was single-blind with unblinded investigators and sponsor, and the sponsor helped design, analyze and write the study. Of 75 treated participants, only 38 finished, and the per-protocol set was just 30 people. Follow-up ended 8 weeks after the final treatment, and the sample was mostly female and White. Here is what the trial can support, what it cannot, and why it is not medical advice or proof of an approved treatment.

Approach 1, macro science, with Palette D, bold color field.

Extreme close-up microscopy-style photograph of a cluster of adipocytes (fat cells). Each is a translucent, pale yellow sphere with a thin membrane, and a few are shrunken and crinkled to suggest apoptosis. The cells sit against a saturated magenta backdrop. The camera is slightly above, at a shallow 30-degree angle, with a very shallow depth of field so the foreground cells are razor sharp and the rest melts into soft bokeh. Hard, clean side light from the left makes the membranes glisten and casts crisp magenta-tinted shadows. One tiny electric green fluorescent speck glows inside a single collapsing cell as a subtle accent. The mood is precise, clinical and curious, with a bold editorial feel. There is no text and no blue cast.
research

CBL-514 Injection Lipolysis: A Phase 2 Map of the Evidence

BY DR. SYNAPSE ·

CBL-514 is an investigational injection that aims to trigger fat-cell apoptosis in a treated abdominal area. In a 2025 Phase 2 trial of 76 randomized participants, it produced large ultrasound-measured fat-volume losses versus saline while mean body weight stayed flat. This hub maps the design, the 2 mg/cm² dosing, the exact efficacy figures with their shrinking denominators, and the company-reported DYRK1b/caspase mechanism. It also spells out the caveats: single-blind design, sponsor involvement, about 49% non-completion, short follow-up and a mostly female sample. Five deeper explainers are linked for readers who want to go further.

**Approach 1 (macro science), Palette D (bold color field).**

Extreme close-up microscopy-style photograph of a cluster of fat cells (adipocytes), rendered as translucent, pearly spheres with thin membranes and tiny lipid droplets inside. One cell in the center is visibly shrinking and blebbing, its membrane crinkled and fragmenting into small beads, the look of apoptosis. A few of the surrounding cells are intact and glossy. The cells sit against a saturated tomato-red backdrop, so the pale yellow-cream spheres stand out sharply. The camera looks straight down at shallow depth of field, with the focal plane on the dying cell and the edges softly blurred. Soft, diffuse top light gives gentle highlights and warm shadows, with no blue cast. One thin electric green fluorescent ring around the central cell's nucleus is the only green accent. The mood is analytical, precise and quietly skeptical.
research

How does CBL-514 work? Here's the science

BY DR. SYNAPSE ·

CBL-514 is not framed as a fat-melting or fat-burning drug. The proposed claim is that it inhibits the survival kinase DYRK1b and pushes fat cells toward apoptosis through caspase 3 and Bax/Bcl-2. That evidence comes from unpublished company reports cited in the Phase 2a and Phase 2 papers, and the chemical structure has not been disclosed. The 2025 Phase 2 trial measured ultrasound fat volume, photos, and safety, with no human biopsy or caspase data. This article separates the molecular hypothesis from what was actually measured in people, including the high dropout and single-blind design.

Approach: the human outcome. Palette: bold color field.

A close, slightly high three-quarter view of a bare abdomen, cropped at the ribs and hips with no face. A hand in an electric green (#00e676) nitrile glove pinches a fold of belly skin and holds a slim syringe with the needle just about to enter. Faint yellow-purple bruising near the injection site hints at the side effects. The torso fills the frame against a flat, saturated teal backdrop that contrasts with the warm skin tones. Soft, even studio light from the left gives gentle shadows and visible skin texture, with fine pores and small hairs. The syringe tip is in sharp focus and the background falls away. No text or markings anywhere. The mood is clinical, unsentimental and skeptical.
research

Does CBL-514 really burn fat? Here's what we know

BY HELIX WARD ·

The 2025 Phase 2 CBL-514 trial did not test weight loss. It tested whether an abdominal injection could cut at least 150 mL of subcutaneous fat volume on ultrasound, and 69.6% (16/23) of treated participants got there at 8 weeks versus 0/16 on placebo. But mean body weight did not fall (+0.02 kg), nearly half of treated participants did not complete the study, and the per-protocol group was just 30 people. Injection-site reactions were common, including discoloration in 71.4% and severe pain in 18.4%. Here is the data-first breakdown of what the trial shows and what it doesn't.

This page is available in